https://scholars.lib.ntu.edu.tw/handle/123456789/473251
標題: | B cells are associated with survival and immunotherapy response in sarcoma | 作者: | Petitprez F. de Reyniès A. Keung E.Z. WEI-WU CHEN Sun C.-M. Calderaro J. YUNG-MING JENG Hsiao L.-P. Lacroix L. Bougoüin A. Moreira M. Lacroix G. Natario I. Adam J. Lucchesi C. Laizet Y. Toulmonde M. Burgess M.A. Bolejack V. Reinke D. Wani K.M. Wang W.-L. Lazar A.J. Roland C.L. Wargo J.A. Italiano A. Sautès-Fridman C. Tawbi H.A. Fridman W.H. |
公開日期: | 2020 | 出版社: | Nature Research | 卷: | 577 | 期: | 7791 | 起(迄)頁: | 556-560 | 來源出版物: | Nature | 摘要: | Soft-tissue sarcomas represent a heterogeneous group of cancer, with more than 50 histological subtypes1,2. The clinical presentation of patients with different subtypes is often atypical, and responses to therapies such as immune checkpoint blockade vary widely3,4. To explain this clinical variability, here we study gene expression profiles in 608 tumours across subtypes of?soft-tissue sarcoma. We establish an immune-based classification on the basis of the composition of the tumour microenvironment and identify five distinct phenotypes: immune-low (A and B), immune-high (D and E), and highly vascularized (C) groups. In situ analysis of an independent validation cohort shows that class E was characterized by the presence of tertiary lymphoid structures that contain T cells and follicular dendritic cells and are particularly rich in B cells. B cells are the strongest prognostic factor even in the context of high or low CD8+ T cells and cytotoxic contents. The class-E group demonstrated improved survival and a high response rate to PD1 blockade with pembrolizumab in a phase 2 clinical trial. Together, this work confirms the immune subtypes in patients with soft-tissue sarcoma, and unravels the potential of B-cell-rich tertiary lymphoid structures to guide clinical decision-making and treatments, which could have broader applications in other diseases. ? 2020, The Author(s), under exclusive licence to Springer Nature Limited. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85078153209&doi=10.1038%2fs41586-019-1906-8&partnerID=40&md5=a3bb8f2b841521039d7955fa4d20d877 https://scholars.lib.ntu.edu.tw/handle/123456789/473251 |
ISSN: | 0028-0836 | DOI: | 10.1038/s41586-019-1906-8 | SDG/關鍵字: | pembrolizumab; cell; decision making; gene expression; immune system; silicon; survival; tumor; Article; B lymphocyte; cancer classification; cancer immunotherapy; cancer prognosis; cancer survival; CD8+ T lymphocyte; cell density; clinical decision making; clinical feature; cohort analysis; controlled study; cytotoxic T lymphocyte; follicular dendritic cell; gene expression profiling; human; human cell; human tissue; immunohistochemistry; lymphocytic infiltration; major clinical study; phase 2 clinical trial; phenotype; priority journal; progression free survival; retrospective study; RNA extraction; soft tissue sarcoma; tertiary lymphoid structure; treatment response; tumor microenvironment; validation study |
顯示於: | 病理學科所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。